Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment

Gefitinib has shown good efficacy in treating recurrent or advanced non-small cell lung cancer (NSCLC), but the drug resistance remains a clinical challenge in medical oncology. In addition, the complex interaction between tumor cells and heterogeneous stromal cells in the adjacent tumor microenviro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Xia, Jia, Lizhou, Wang, Tengqi, Zhang, Yulian, Zhao, Wei, Wang, Xiangcheng, Chen, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317539/
https://www.ncbi.nlm.nih.gov/pubmed/34335947
http://dx.doi.org/10.7150/jca.57711

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317539/
https://www.ncbi.nlm.nih.gov/pubmed/34335947
http://dx.doi.org/10.7150/jca.57711

Ejemplares similares